Pefloxacin is a fluorinated quinolone that is structurally related to nalidixic acid. It can be administered both orally and intravenously, and has a broad spectrum of in vitro activity against Gram-negative organisms and staphylococci. The pharmacokinetic profile of pefloxacin is characterised by high bioavailability after oral administration, a long half-life and good penetration of tissue and body fluids.
Data from mainly non-comparative studies suggest that pefloxacin has the potential for use in a variety of serious or difficult-to-treat and nosocomially acquired infections in hospitalised and immunocompromised patients. Such infections have included respiratory tract, urogenital tract, and bone and joint infections, septicaemia and surgical infections, in addition to severe Gram-negative infections in neutropenic cancer patients. Pefloxacin demonstrates comparable efficacy with ampicillin combined with gentamicin in upper gynaecological tract infections, ceftazidime in nosocomially acquired Gram-negative infections and co-trimoxazole (trimethoprim + sulphamethoxazole) in uncomplicated urinary tract infections and typhoid fever.
Although the place of pefloxacin in this new and expanding class of 4-quinolone antibacterial drugs has yet to be defined and it appears to be a well-tolerated and useful drug for the treatment of serious infections in hospitalised patients, further studies are awaited with interest for confirmation of these preliminary results.
Pefloxacin is a fluorinated quinolone which is structurally related to nalidixic acid. Most species of Enterobacteriaceae are susceptible or moderately susceptible to pefloxacin (MIC90 ≤ 2 mg/L); Providencia rettgeri is only moderately susceptible to the drug. For most species of Enterobacteriaceae the potency of pefloxacin was equivalent to that of enoxacin, ofloxacin, norfloxacin and cefotaxime, less than that of ciprofloxacin, and greater than that of nalidixic acid, ampicillin, amikacin, gentamicin and ceftazidime. Pefloxacin is a potent inhibitor of Neisseria gonorrhoeae and N. meningitidis, while strains of Acinetobacter are susceptible or moderately susceptible to the drug. Branhamella catarrhalis and Campylobacter species are susceptible or moderately susceptible to pefloxacin as well as to the other 4-quinolones tested. Haemophilus ducreyi is highly susceptible (MIC90 ≤ 0.12 mg/L) while H. influenzae is susceptible to pefloxacin. The activity of pefloxacin against Pseudomonas aeruginosa (MIC90 2 to 16 mg/L) is similar to that of enoxacin and norfloxacin, but less than that of ciprofloxacin and ofloxacin. For other species of Pseudomonas the susceptibility to pefloxacin is variable, with MIC90 values ranging from 1 to 64 mg/L. Other Gram-negative species including Aeromonas hydrophila, Legionella, Plesiomonas, Capnocytophaga, Agrobacter and Vibrio species are susceptible to pefloxacin, but Gardnerella vaginalis is resistant.
Staphylococcal strains, including Staphylococcus epidermidis and isolates of Staphylococcus aureus resistant to other antibacterials, are susceptible or moderately susceptible to pefloxacin, but there is an increasing percentage of resistant strains emerging. Streptococcus species including enterococci have only moderate sensitivity to pefloxacin, with MIC90 values ranging from 3.1 to 32 mg/L. Other Gram-positive species such as Listeria monocytogenes and Nocardia asteroides are resistant, whereas Mycobacterium tuberculosis and some other species of mycobacteria are usually only moderately susceptible to pefloxacin. Pefloxacin is inactive against most anaerobic species, including Bacteroides, Clostridium and Fusobacterium.
Pefloxacin is not active against Chlamydia trachomatis, Mycoplasma hominis and Ureaplasma urealyticum, with MIC90 values of 2 to 8, 16 and 2 to 8 mg/L, respectively; ofloxacin and ciprofloxacin are generally more active than pefloxacin in inhibiting these species.
Bacterial resistance to non-quinolone drugs such as penicillin, oxacillin and methicillin has little influence on the in vitro activity of pefloxacin but there is cross resistance, as shown using nalidixic acid-resistant isolates. Inoculum size has only a minor influence on the in vitro activity of pefloxacin but acidic pH and addition of calcium or magnesium ions has been shown to reduce its activity. Pefloxacin is rapidly bactericidal and has shown no synergistic in vitro effects in combination with other antibacterials, including cephalosporins and aminoglycosides, against Gram-negative and Gram-positive isolates. Amikacin, ceftazidime and piperacillin prevented the emergence of resistance to pefloxacin. Pefloxacin inhibits DNA gyrase activity, preventing the supercoiling of DNA and so interfering with bacterial replication, but alternative mechanisms of action such as the capacity to penetrate the bacterial membrane probably also contribute to its antibacterial effects.
Pefloxacin was shown to have good in vivo activity against S. aureus infections in mice, P. aeruginosa infections in neutropenic guinea-pigs, Escherichia coli-induced endocarditis, mice infected with Mycobacterium leprae and guinea-pig legionellosis.
After administration of single oral doses of pefloxacin 400mg, to healthy volunteers, maximum plasma concentrations of 3.84 to 6.6 mg/L occur within 60 to 90 minutes. In a multiple-dose study both intravenous and oral routes of administration of pefloxacin 400mg produced approximate maximum plasma concentrations of 10 mg/L and AUC values were similar after both routes, indicative of complete bioavailability. Steady-state concentrations were achieved within 48 hours. Plasma trough concentrations 2 to 3 days after the start of multiple-dose 400mg administration were 2.1 to 3.8 mg/L, which are higher than the MIC90s for the majority of susceptible pathogens.
The volume of distribution has been calculated to range from 1.7 to 1.9 L/kg. Tissue pefloxacin concentrations are equivalent or higher than plasma concentrations for blister fluid, bone, brain, cardiac tissue, cerebrospinal fluid, prostate, saliva and sputum. Pefloxacin effectively penetrates extravascular spaces and is only 20 to 30% protein bound.
Pefloxacin is metabolised extensively to form the principal N-demethyl pefloxacin (norfloxacin) and N-oxide metabolites. Following single-dose administration of radiolabelled pefloxacin 70% and 25% of radioactivity was detected in urine and faeces, respectively, within 7 days. Only 8 to 9% of an administered dose appears in the urine as unchanged pefloxacin. Total urinary recovery of parent drug and metabolites was 59% of an administered dose, and renal clearance was 0.6 L/h and was independent of the route of administration. In addition, biliary excretion of pefloxacin and its metabolites also occurs. The elimination half-life following administration of single oral doses of pefloxacin 400mg ranged from 8.6 to 13 hours, increasing to approximately 14 to 15 hours after multiple dosing. In patients with impaired hepatic function plasma clearance of pefloxacin was reduced as further indicated by an increase in elimination half-life. In contrast, studies have shown impaired renal function to have minimal influence on the pharmacokinetics of pefloxacin. However, further studies are needed to verify whether alteration of dosage or dosing interval of pefloxacin is necessary in patients with renal dysfunction.
The majority of clinical trials with oral or intravenous pefloxacin have been conducted in hospitalised patients with a range of infectious conditions including nosocomially acquired infections, serious or difficult-to-treat infections, and infections in immunocompromised patients. In most cases these studies have been carried out under non-blind conditions and with limited comparisons to other antibacterial drugs.
In the treatment of patients with respiratory tract infections pefloxacin 800 to 1200mg daily produced clinical cure rates of 58 to 70% and bacteriological eradication rates ranging from 70 to 94%. Resistant strains of S. pneumoniae and P. aeruginosa were responsible for some of the treatment failures, and 3 studies reported superinfections in 7.5, 22 and 25% of patients. Gynaecological infections, as well as complicated upper or lower urinary tract infections, pelvic infections associated with the genital tract, and acute gonococcal infections were responsive in 72 to 94% of patients treated with pefloxacin 800 to 1200mg daily. In 2 comparative studies pefloxacin 800mg daily was as effective as daily ampicillin 2g combined with gentamicin 180 to 240mg in upper gynaecological tract infections, producing clinical cure rates of 93.3 and 94.4%, respectively, and as effective as co-trimoxazole 160/800mg twice daily in uncomplicated urinary tract infections.
In the treatment of chronic osteitis, chronic osteomyelitis and other bone and joint infections, treatment with pefloxacin 400mg twice a day for up to 18 months produced a clinical cure in 87 to 100% of patients. In a limited number of immunologically compromised patients successful results have been obtained with pefloxacin in non-comparative trials in the prophylaxis and treatment of fever or infections, particularly those caused by Gram-negative bacteria. In patients with septicaemia of varying focal origin caused by Staphylococcus aureus, streptococci, Enterobacteriaceae and Pseudomonas aeruginosa, treatment with pefloxacin 800 to 1200mg daily produced a favourable response in 76 to 100% of patients and eradication of 86 to 96% of bacteriological isolates.
Pefloxacin 800mg was as effective as co-trimoxazole 320/1600mg in the treatment of typhoid fever with both drugs resulting in a clinical cure in 100% of patients, but pefloxacin produced a more rapid onset of apyrexia than co-trimoxazole allowing a shortening of the treatment time. In the treatment of patients with nosocomially acquired Gram-negative infections, which included urinary tract infections, bronchopneumonia, deep soft tissue phlegmon, osteoarticular infections, intra-abdominal infections, chronic otitis media and acute cholangitis, pefloxacin 400mg every 8 or 12 hours was similar in efficacy to ceftazidime 2g every 8 hours and cefotaxime 1g 4 times a day.
Pefloxacin is generally well tolerated, with most adverse effects being of mild to moderate severity and transient in nature. Gastrointestinal disturbances were the most frequent adverse effects experienced, accounting for over 50% of 186 reactions reported in a survey of 1437 patients. Nausea, vomiting, gastralgia, skin reactions and neurological reactions were the most frequently cited adverse effects, and 3% of patients withdrew from therapy as a result of adverse reactions. Photosensitivity developed in 0.83% of patients in this survey, and in a long term study 11 of 36 patients developed pruriginous and erythematous eruptions on the face and forearms after exposure to sunlight.
Minor changes in laboratory values following pefloxacin treatment have been reported, but these were generally not considered to be drug related. Pefloxacin does not adversely affect the gastrointestinal microflora through selection of resistant species.
Dosage and Administration
The recommended dosage of pefloxacin is 400mg administered twice a day orally with meals or intravenously. Parenteral pefloxacin should be administered as a 1-hour intravenous infusion, with the drug mixed with a 5% glucose solution and not saline. Where appropriate a loading dose of 800mg may be used on starting treatment to achieve steady-state concentrations of the drug. In patients with reduced hepatic function dosage adjustments should be made. Patients with impaired renal function may also require dosage adjustment.
As a result of the pharmacokinetic interactions between pefloxacin and theophylline, it is recommended that theophylline concentrations should be monitored in those patients receiving concomitant treatment. In addition, patients receiving pefloxacin and coumarin should have their clotting times monitored. The absorption of pefloxacin may be reduced by the concomitant administration of antacids, especially those containing aluminium or magnesium ions. A reduction in pefloxacin clearance and an increase in its elimination half-life occur with concomitant cimetidine administration.
Pefloxacin is contraindicated in children or adolescents in the growing phase and the drug should not be administered to pregnant women or nursing mothers.
KeywordsQuinolones Ceftazidime Norfloxacin Nalidixic Acid Antimicrobial Chemotherapy
Unable to display preview. Download preview PDF.
- Aldridge KE, Schiro DD, Sanders CV. Pefloxacin (RB 1589): an in vitrocomparison with other oral antimicrobial agents and imipenem. Current Therapeutic Research 40: 1103–1113, 1986Google Scholar
- Arpi M, Gahrn-Hansen B, Sogaard P, Bentzon MW. Comparative in vitroactivities of pefloxacin, ofloxacin, enoxacin and ciprofloxacin against 256 clinical isolates. Acta Pathologica Microbiologica et Immunologica Scandinavica Section B 95: 141–146, 1987Google Scholar
- Bernard E, Dellamonica P, Etesse H, Garraffo R, Beziau H, et al. Efficacy of ofloxacin and pefloxacin for the treatment of bone infections. Reviews of Infectious Diseases 10 (Suppl. 1): 188–189, 1988Google Scholar
- Bouanchaud DH, Rolin O. Bactericidal activity of pefloxacin compared with ten other antibiotics on Staphylococcus aureusand Pseudomonas aeruginosa.Drugs Under Experimental and Clinical Research 10: 669–676, 1984Google Scholar
- Buré A, Desplaces N, Pangon B, Dournon E. In vitroactivity of ciprofloxacin, pefloxacin and ofloxacin against Legionella.14th International Congress of Chemotherapy, Tokyo, June 23–28, 1985Google Scholar
- Courvalin P, Derlot E, Chabbert YA. Cross resistance to quinolone derivatives of Enterobacteriaceae and Pseudomonasmutants selected on pefloxacin and ciprofloxacin. 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, 1984Google Scholar
- Cullmann W, Stieglitz M, Baars B, Opferkuch W. Comparative evaluation of recently developed quinolone compounds — with a note on the frequency of resistant mutants. Chemotherapy (Basel) 31: 19–28, 1985Google Scholar
- Debbia E, Schito GC, Nicoletti G, Speciale A. In vitroactivity of pefloxacin against Gram-negative and Gram-positive bacteria in comparison with other antibiotics. Chemoterapia 6: 319–323, 1987Google Scholar
- Desplaces N, Gutmann L, Acar JF. Treatment of chronic osteomyelitis (CO.) due to Staphylococcusspp. or Gram-negative baeteria with a new quinolone: pefloxacin (PEF). 14th International Congress of Chemotherapy, Kyoto, June 23–28, 1985Google Scholar
- Desplaces N, Mamoudy P, Leonard P, Kitzis MD, Gutmann L. Pefloxacin in the treatment of bone and joint infections due to Enterobacteriaceae. 15th International Congress of Chemotherapy, Istanbul, July 20–25, 1987Google Scholar
- Dow J, Frydman AM, Djebbar F, Gaillot J. Single- and multiple-dose pharmacokinetics of pefloxacin in elderly patients. Reviews of Infectious Diseases 10 (Suppl. 1): 107, 1988Google Scholar
- Fournier G, Mantz JM, Kopferschmitt J, Ghanassia JP. Pefloxacin in the impiric treatment of sepsis of various origin. 15th International Congress of Chemotherapy, Istanbul, July 20–25, 1987Google Scholar
- Gevaudan MJ, Mallet MN, Gulian C, Terriou Ph, Lagier P, et al. Étude de la sensibilité de sept espèces de mycobactéries aux nouvelles quinolones. Pathologie 36: 477–481, 1988Google Scholar
- Giamarellou H, Galanakis N, Perdikaris G, Tsagaraki Ch. Comparative efficacy of pefloxacin versus ceftazidime in a variety of mostly nosocomial acquired Gram-negative infections. 17th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, 1987Google Scholar
- Gluckman E, Carazzana M, Devergie A, Meletis J, Arlet G, et al. Prevention des infections bactériennes apres greffe de moelle osseuse par antibiotiques oraux a large spectre absorbables (pefloxacine, penecilline) ou non absorbables (cephalosporines, gentamicine, bacitracine). Pathologie Biologie 36: 902–906, 1988PubMedGoogle Scholar
- Griggs D, Lister D, Andrews JM, Wise R. Pharmacokinetics and inflammatory-fluid penetration of pefloxacin. Reviews of Infectious Diseases 10 (Suppl. 1): 98, 1988Google Scholar
- Guelpa-Lauras C-C, Perani EG, Giroir A-M, Grosset JH. Activities of pefloxacin and ciprofloxacin against Mycobacterium lepraein the mouse. International Journal of Leprosy 55: 70–77, 1987Google Scholar
- Guy H, Caillot D, Solary E, Bielefeld Ph, Portier H, et al. Association d’une céphalosporine de troisième génération (céfo-taxime ou ceftazidime) et d’une nouvelle quinolone (péfloxacine) dans le traitement des épisodes fébriles des malades neutropéniques (37 cas). La Presse Médicale 16: 2172–2175, 1987PubMedGoogle Scholar
- Kayser FM. The quinolones: mode of action and mechanisms of resistance. Research and Clinical Forums 7: 17–27, 1985Google Scholar
- Korinek AM, Montay G, Bianchi A, Guggiari M, Grob R, et al. Penetration of pefloxacin into human brain tissue. Reviews of Infectious Diseases 10 (Suppl. 1): 257, 1988Google Scholar
- Laredo Filho J. Efficacy and safety evaluation of pefloxacin in the treatment of chronic osteitis, with a prolonged follow-up. 15th International Congress of Chemotherapy, Istanbul, July 20–25, 1987Google Scholar
- Leleux A, Gerain J, Daneau M, Van der Auwera P, Meunier F. Pefloxacin for selective decontamination in neutropenic cancer patients (NCPTS). 15th International Congress of Chemotherapy, Istanbul, July 20–25, 1987Google Scholar
- McEwan SR, Davey PG. Ciprofloxacin and tenosynovitis. Lancet 2: 900, 1988 au]Meunier F, Aoun M, Delbaye N, Van der Auwera P, Klastersky J. Therapy of Gram-negative bacillary septicaemia with pefloxacin in non neutropenic patients. 2nd International Symposium on New Quinolones, Geneva, August 25–27, 1988PubMedCrossRefGoogle Scholar
- Morel C, Vergnaud M, Langeard V, Benard Y. Péfloxacine: diffusion dans le mucus bronchique. Pathologie Biologie 32: 516–519, 1985Google Scholar
- Moskowitz B, Djebbar F. Pefloxacin in the treatment of serious and/or difficult to treat infections. 15th International Congress of Chemotherapy, Istanbul, July 20–25, 1987Google Scholar
- NCCLS. Thornsberry C, et al. (Eds) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. National Committee for Clinical Laboratory Standards Publication M7-A, Villanova Pa., NCCLS, 1985Google Scholar
- Pallavicini F, Antinori A, Federico G, Fantoni M, Nervo P. Influence of two quinolones, ofloxacin and pefloxacin, on human myelopoiesis in vitro.Antimicrobial Agents and Chemotherapy 33: 122–123, 19Google Scholar
- Peixoto S. Pefloxacin versus ampicillin + gentamicin in the treatment of upper gynecological tract infections. 15th International Congress of Chemotherapy, Istanbul, July 20–25, 1987Google Scholar
- Pfeiffer M, Treutner KP. Pefloxacin in the treatment of severe therapy-resistant infections in general surgery. 15th International Congress of Chemotherapy, Istanbul, July 20–25, 1987Google Scholar
- Preheim LC, Cuevas TA, Roccaforte JS, Mellencamp MA, Bittner MJ. Oral ciprofloxacin in the treatment of elderly patients with complicated urinary tract infections due to trimethoprim/ sulphamethoxazole-resistant bacteria. American Journal of Medicine 82 (Suppl. 4A): 295–300, 1987PubMedGoogle Scholar
- Ramirez FJH, Loperena HH, Regalado AS, Sánchez CJ, Valdez AC. Estudio clinico abierto randomizado para determinar eficacia y seguridad de pefloxacina vs cefotaxima en el tratamiento de infecciones severas. Investigation Médica Internacional 15: 75–84, 1988Google Scholar
- Rodante O. Clinical experience with pefloxacin in severe systemic infections in intensive care units. 14th International Congress of Chemotherapy, Kyoto, Jun 23–28, 1985Google Scholar
- Sande M, Acar JF, Nishino T. A new quinolone compound: antimicrobial and clinical activity. 14th International Congress of Chemotherapy, Kyoto, June 23–28, 1985Google Scholar
- Sanson-Le Pors MJ, Casin IM, Thebault MC, Arlet G, Perol Y. In vitroactivities of U-63366, a spectinomycin analogue; roxithromycin (RU 28965), a new macrolide antibiotic; and five quinolone derivatives against Haemophilus ducreyi.Antimicrobial Agents and Chemotherapy 30: 512–513, 1986CrossRefGoogle Scholar
- Segev S, Pitlick SD, Rubinstein E. Pefloxacin for Gram-negative infections in compromised patients. 15th International Congress of Chemotherapy, Istanbul, July 20–25, 1987Google Scholar
- Smith JT, Ratcliffe NT. Effect of pH and magnesium on the in vitro activity of ciprofloxacin. In Neu HC & Wenta H (Eds) Proceedings of the 1st International Ciprofloxacin Workshop, Amsterdam, pp. 12–16, Excerpta Medica, 1986Google Scholar
- Sörgel F, Koch U, Metz R, Staphan U. Cimetidine inhibits the hepatic metabolism of pefloxacin. 26th International Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 28 September–1 October, 1986Google Scholar
- Sörgel F, Mahr G, Stephan U, Koch HU, Wiesemann HG. Absolute bioavailability and pharmacokinetics of pefloxacin in healthy volunteers. Reviews of Infectious Diseases 10 (Suppl. 1): 93, 1988Google Scholar
- Suerbaum S, Leving H, Kroll H-P, Gmeiner J, Opferkuch W. Influence of β-lactam antibiotics and ciprofloxacin on cell envelope of Escherichia coli.Antimicrobial Agents and Chemotherapy 31: 1106–1110, 19Google Scholar
- Suermondt G, Denamur E, Laurans G, Orfila J. Etude in vitrode trois fluoroquinolones sur Branhamella catarrhalis.Pathologie Biologie 36: 647–650, 19Google Scholar
- Thabaut A, Meyran M. Comparative bactericidal activity of new quinolones and other antibiotics. International Symposium on New Quinolones, Geneva, 1986Google Scholar
- Thauvin C, Lemeland J-F, Humbert G, Fillastre J-P. Efficacy of pefloxacin-fosfomycin in experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.Antimicrobial Agents and Chemotherapy 32: 919–921, 19Google Scholar
- Turgeon PL, Desrochers C, Mantha R. Comparative in vitroactivity of fluoroquinolones and other parenteral antimicrobial agents against urinary bacterial isolates and oxacillin-resistant Staphylococcus aureus.Current Therapeutic Research 41: 670–678, 1987bGoogle Scholar
- Turgeon PL, Gaudreau CL, Mantha R. Comparative in vitroactivity of four quinolones and four other agents against enteropathogens. Current Therapeutic Research 4: 584–588, 1987aGoogle Scholar
- Van der Auwera P, Grenier P, Glupczynski Y, Pierard D. In vitroactivity of lomefloxacin in comparison with pefloxacin and ofloxacin. Journal of Antimicrobial Chemotherapy, in press, 1989Google Scholar
- Van der Auwera P, Husson M, Klastersky J. Bactericidal activity and killing rate of serum in volunteers receiving pefloxacin alone or in combination with ceftazidime, piperacillin, or mezlocillin against Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 21: 49–55, 1988PubMedCrossRefGoogle Scholar
- Vanderdonckt J, Cordier R, Hillebrand A. Clinical evaluation of pefloxacin in hospital acquired lower respiratory tract infections. 15th International Congress of Chemotherapy, Istanbul, July 20–25, 1987Google Scholar
- Vargas FS, Fiss E, Cukier A, Maia F, Saad E, et al. Pefloxacin treatment of severe lower respiratory tract infections. 15th International Congress of Chemotherapy, Istanbul, July 20–25, 1987Google Scholar
- Wijnands WJA. The fluoroquinolones in the treatment of lower respiratory tract infections. Pharmaceutical, clinical and bacteriological aspects. PhD thesis, University of Nijmegan, Nijmegan, 1987Google Scholar
- Wijnands WJA, Vree TB. Interaction between the fluoroquinolones and the bronchodilator theophylline. Journal of Antimicrobial Chemotherapy 22 (Suppl. C): 104–109, 1988Google Scholar
- Wittenberger R, Bauernfeind A. Treatment of urinary tract infections with pefloxacin: efficacy, safety and pharmacokinetics. 14th International Congress of Chemotherapy, Kyoto, June 23–28, 1985Google Scholar
- Wittke R, Schmidt P, Wipprecht H. Pefloxacin in the treatment of surgically related infections in the elderly. 15th International Congress of Chemotherapy, Istanbul, July 20–25, 1987Google Scholar
- Wolff M, Regnier B, Nkam M, et al. Pefloxacin penetration into cerebrospinal fluid in patients with bacterial meningitis. Program and Abstracts of the 23rd ICAAC, Las Vegas, Oct 24–26, 1983Google Scholar
- Zuccarelli M, Simeon de Buochberg M, Maillols M, Armynot du Chatelet AM, Attisso MA. Cinétiques de bactericidie comparées de la ciprofloxacine, de l’ofloxacine et de la péfloxacine seules et en association sur des souches streptocoques du groupe D. Pathologie Biologie 36: 403–409, 1988PubMedGoogle Scholar